Aurobindo Pharma Ltd

Aurobindo Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Aurobindo Pharma Ltd

₹ 1,426 -0.66%
29 May - close price
aurobindo.com BSE: 524804 NSE: AUROPHARMA
About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

Key Points

Leading Pharmaceutical Company
The company is India’s 2nd-largest listed pharma company based on revenue & the largest generics company in the US. It is ranked among the top 10 generic companies in 8 European countries. [1]

Website BSE NSE
  • Market Cap ₹ 82,846 Cr.
  • Current Price ₹ 1,426
  • High / Low ₹ 1,550 / 1,016
  • Stock P/E 34.1
  • Book Value ₹ 391
  • Dividend Yield 0.28 %
  • ROCE 13.0 %
  • ROE 11.2 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Stock is trading at 3.65 times its book value
  • The company has delivered a poor sales growth of -6.73% over past five years.
  • Company has a low return on equity of 10.1% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
2,406 2,391 2,669 2,692 2,894 2,460 2,825 2,917 2,732 2,848 2,790 2,747 2,787
1,830 1,968 2,124 2,210 2,119 1,961 2,104 2,203 2,135 2,052 2,065 1,958 2,005
Operating Profit 576 422 545 482 775 499 721 713 597 796 725 789 781
OPM % 24% 18% 20% 18% 27% 20% 26% 24% 22% 28% 26% 29% 28%
326 113 103 331 123 65 123 54 114 84 160 113 214
Interest 32 32 37 61 53 51 52 66 61 60 57 48 47
Depreciation 67 60 66 64 65 67 68 68 94 70 71 72 72
Profit before tax 804 444 546 687 780 446 724 633 556 750 755 782 876
Tax % 20% 24% 24% 9% 26% 26% 26% 25% 27% 25% 23% 26% 21%
645 336 416 624 579 329 538 472 408 559 581 582 692
EPS in Rs 11.01 5.74 7.10 10.65 9.88 5.62 9.25 8.13 7.03 9.63 10.01 10.02 11.92
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
8,069 9,158 9,607 10,270 12,258 13,371 15,824 11,287 8,457 10,646 10,933 11,172
5,816 6,705 7,215 7,600 9,838 10,670 11,704 9,783 6,952 8,422 8,376 8,080
Operating Profit 2,253 2,453 2,392 2,670 2,420 2,700 4,120 1,504 1,505 2,224 2,558 3,092
OPM % 28% 27% 25% 26% 20% 20% 26% 13% 18% 21% 23% 28%
65 187 118 81 189 386 590 565 429 670 328 570
Interest 132 229 45 53 231 243 29 17 75 183 230 213
Depreciation 245 263 286 355 413 473 488 415 243 255 297 285
Profit before tax 1,940 2,148 2,179 2,343 1,965 2,370 4,193 1,637 1,616 2,457 2,358 3,164
Tax % 22% 24% 22% 23% 22% 21% 26% 11% 24% 20% 26% 24%
1,516 1,627 1,707 1,813 1,530 1,877 3,113 1,455 1,227 1,954 1,747 2,415
EPS in Rs 25.96 27.80 29.13 30.94 26.11 32.03 53.13 24.83 20.94 33.35 30.08 41.58
Dividend Payout % 9% 9% 9% 8% 10% 9% 8% 36% 36% 13% 0% 0%
Compounded Sales Growth
10 Years: 2%
5 Years: -7%
3 Years: 10%
TTM: 2%
Compounded Profit Growth
10 Years: 4%
5 Years: -5%
3 Years: 26%
TTM: 39%
Stock Price CAGR
10 Years: 6%
5 Years: 7%
3 Years: 29%
1 Year: 24%
Return on Equity
10 Years: 13%
5 Years: 9%
3 Years: 10%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 29 59 59 59 59 59 59 59 59 59 58 58
Reserves 5,330 6,807 8,378 9,924 11,292 12,994 15,866 17,059 17,975 19,664 20,476 22,660
3,285 4,165 3,054 3,719 4,520 3,741 4,028 1,895 4,203 2,861 4,647 4,285
1,582 1,534 1,533 2,092 2,270 2,770 3,237 2,589 2,822 2,570 2,332 2,276
Total Liabilities 10,226 12,566 13,023 15,794 18,141 19,564 23,189 21,601 25,059 25,154 27,513 29,279
2,190 2,568 3,212 3,393 4,150 4,418 4,472 3,586 3,688 2,419 2,337 2,544
CWIP 227 742 907 1,144 789 815 735 225 239 133 88 229
Investments 1,013 1,183 1,682 1,968 2,339 2,527 5,010 6,584 8,105 13,393 15,210 17,562
6,796 8,072 7,222 9,289 10,863 11,804 12,972 11,206 13,027 9,209 9,879 8,945
Total Assets 10,226 12,566 13,023 15,794 18,141 19,564 23,189 21,601 25,059 25,154 27,513 29,279

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
590 1,185 2,457 922 530 2,201 2,994 3,727 1,816 1,715 1,646 2,933
-624 -1,390 -1,542 -991 -1,301 -948 -2,650 -1,615 -3,230 -152 -2,050 -2,025
35 515 -1,329 440 599 -1,255 -28 -2,448 1,719 -1,837 616 -1,072
Net Cash Flow 1 310 -414 371 -171 -1 316 -335 306 -274 212 -164
Free Cash Flow 48 19 1,440 202 -357 1,568 2,646 3,753 1,481 1,293 1,454 2,475
CFO/OP 45% 68% 123% 54% 42% 96% 88% 294% 141% 104% 91% 120%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 168 175 143 159 156 158 137 128 197 129 140 138
Inventory Days 207 207 191 273 235 242 244 210 335 148 154 161
Days Payable 111 109 96 130 109 107 104 104 179 112 116 125
Cash Conversion Cycle 264 273 239 301 282 293 277 234 353 166 177 174
Working Capital Days 108 84 92 106 107 132 118 181 126 65 32 51
ROCE % 27% 24% 20% 19% 15% 16% 23% 9% 8% 12% 11% 13%

Insights

In beta
Mar 2015 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Cumulative US ANDA Filings
Number

Log in to view insights

Please log in to see hidden values.

Login
Cumulative US DMF Filings
Number
Cumulative Europe Formulations Filings
Number
Number of Manufacturing Facilities
Number
Formulation Manufacturing Capacity
Billion Units
R&D Spend as % of Sales
%
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
51.84% 51.84% 51.84% 51.84% 51.80% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82%
24.12% 22.45% 20.72% 18.01% 16.73% 16.59% 16.29% 15.33% 14.38% 14.21% 13.95% 15.24%
15.73% 18.29% 20.60% 23.28% 24.77% 25.14% 25.21% 26.23% 26.93% 27.60% 27.66% 25.82%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.05%
8.31% 7.43% 6.85% 6.87% 6.69% 6.45% 6.67% 6.61% 6.88% 6.37% 6.55% 7.08%
No. of Shareholders 2,93,2142,59,6382,41,9442,44,5752,38,6222,48,4882,57,9622,69,3232,72,2082,47,6622,36,8592,41,298

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls